Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Provides historical context on preclinical safety attrition; leaves open relevance to current cardiovascular drug pipelines.
The Fifth International World Pharmaceutical Congress was held in the Philadelphia Convention Centre during May 23 - 25 2006. In addition to exhibits and three plenary presentations, there were six concurrent sessions. In this report the author summarises some of the highlights of the conference entitled 'The impact of preclinical drug safety on R&D productivity'. This focused session gave a broad overview of the present state and future directions of drug safety assessment, both from a technical and organisational perspective.
No takes yet. Share an insight, caveat, or question.
Orest Hurko (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: